5.21
price up icon0.10%   0.00
after-market After Hours: 5.21
loading
Third Harmonic Bio Inc stock is traded at $5.21, with a volume of 248.54K. It is up +0.10% in the last 24 hours and up +0.87% over the past month. Third Harmonic Bio Inc is a biopharmaceutical company focused on the development of the next wave of medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. The company's product candidate, THB001, is a selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. Its other product candidate THB335, is a potent, selective, oral small molecule KIT inhibitor, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway, and gastrointestinal tract.
See More
Previous Close:
$5.21
Open:
$5.2
24h Volume:
248.54K
Relative Volume:
0.44
Market Cap:
$235.13M
Revenue:
-
Net Income/Loss:
$-32.74M
P/E Ratio:
-6.3537
EPS:
-0.82
Net Cash Flow:
$-24.89M
1W Performance:
+0.68%
1M Performance:
+0.87%
6M Performance:
-59.13%
1Y Performance:
-61.79%
1-Day Range:
Value
$5.195
$5.23
1-Week Range:
Value
$5.17
$5.23
52-Week Range:
Value
$3.18
$16.02

Third Harmonic Bio Inc Stock (THRD) Company Profile

Name
Name
Third Harmonic Bio Inc
Name
Phone
(209) 727-2457
Name
Address
1700 MONTGOMERY STREET, SAN FRANCISCO
Name
Employee
31
Name
Twitter
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
THRD's Discussions on Twitter

Compare THRD with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
THRD
Third Harmonic Bio Inc
5.21 234.66M 0 -32.74M -24.89M -0.82
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.58 25.81B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
441.85 111.46B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.35 40.37M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
81.16 6.19B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
489.52 64.44B 14.09B 4.50B 2.96B 39.28

Third Harmonic Bio Inc Stock (THRD) Upgrades & Downgrades

Date Action Analyst Rating Change
Mar-28-25 Downgrade Stifel Buy → Hold
Feb-12-25 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-11-25 Downgrade Raymond James Outperform → Mkt Perform
Aug-09-24 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-18-24 Initiated Stifel Buy
Jun-07-24 Initiated Raymond James Outperform
Dec-16-22 Downgrade Jefferies Buy → Hold
Dec-15-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-10-22 Initiated Cowen Outperform
Oct-10-22 Initiated Jefferies Buy
Oct-10-22 Initiated Morgan Stanley Overweight
View All

Third Harmonic Bio Inc Stock (THRD) Latest News

pulisher
May 28, 2025

Cancer drugmaker iTeos to shut down - BioPharma Dive

May 28, 2025
pulisher
May 22, 2025

Layoff Tracker: Eikon Cuts Workforce by 15%, Citing ‘External Forces’ - BioSpace

May 22, 2025
pulisher
May 16, 2025

It’s been three months without a biotech IPO - Endpoints News

May 16, 2025
pulisher
May 08, 2025

THIRD HARMONIC BIO Earnings Results: $THRD Reports Quarterly Earnings - Nasdaq

May 08, 2025
pulisher
May 08, 2025

Third Harmonic Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 08, 2025
pulisher
May 05, 2025

Third Harmonic Bio Announces Plan of Liquidation and Dissolution - ADVFN

May 05, 2025
pulisher
May 02, 2025

Here’s Why Third Harmonic Bio (THRD) Fell in Q1 - Insider Monkey

May 02, 2025
pulisher
Apr 29, 2025

Acelyrin should liquidate instead of merging with Alumis, investor says - BioPharma Dive

Apr 29, 2025
pulisher
Apr 27, 2025

Third Harmonic Bio’s CSO Christopher Dinsmore Steps Down - MSN

Apr 27, 2025
pulisher
Apr 25, 2025

Fierce Biotech Layoff Tracker 2025: Caribou cuts 32% of staff; Mural lays off 90% - Fierce Biotech

Apr 25, 2025
pulisher
Apr 23, 2025

Third Harmonic Bio CSO steps down, enters separation agreement - Investing.com Australia

Apr 23, 2025
pulisher
Apr 23, 2025

Third Harmonic Bio CSO steps down, enters separation agreement By Investing.com - Investing.com India

Apr 23, 2025
pulisher
Apr 21, 2025

Dupixent bounces back in treating hives with FDA approval - BioWorld MedTech

Apr 21, 2025
pulisher
Apr 18, 2025

New fund Alis offers struggling biotechs an off-ramp: Finance Report - BioCentury

Apr 18, 2025
pulisher
Apr 17, 2025

Finance Watch: Investors Push ESSA Pharma, Elevation Oncology To Wind Down - insights.citeline.com

Apr 17, 2025
pulisher
Apr 16, 2025

SF biotech company, once worth nearly $1 billion, plans to shut down - SFGATE

Apr 16, 2025
pulisher
Apr 16, 2025

Biotech Alert: Searches spiking for these stocks today - TipRanks

Apr 16, 2025
pulisher
Apr 16, 2025

Third Harmonic Bio (THRD) Plans Liquidation; Significant Search Surge in Biotech Sector | ARTL Stock News - GuruFocus

Apr 16, 2025
pulisher
Apr 15, 2025

Third Harmonic Bio (THRD) Seeks Stockholder Approval for Liquida - GuruFocus

Apr 15, 2025
pulisher
Apr 15, 2025

Third Harmonic Bio plans to liquidate the company, sell urticaria treatment - MSN

Apr 15, 2025
pulisher
Apr 15, 2025

Third Harmonic Bio, Inc. Liquidation and Shareholder Distribution: Analyst Maintains Hold Rating Amid Strategic Uncertainties - TipRanks

Apr 15, 2025
pulisher
Apr 15, 2025

Third Harmonic's shutdown, Coherus and Xoma drug sales connectedBizwomen - The Business Journals

Apr 15, 2025
pulisher
Apr 15, 2025

Third Harmonic Bio leaps as it reveals liquidation plan - The Pharma Letter

Apr 15, 2025
pulisher
Apr 15, 2025

Big moves by small biotechs signal potential shift for investorsSan Francisco Business Times - The Business Journals

Apr 15, 2025
pulisher
Apr 15, 2025

Top 3 Health Care Stocks You May Want To Dump This Quarter - Benzinga

Apr 15, 2025
pulisher
Apr 15, 2025

Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered - MSN

Apr 15, 2025
pulisher
Apr 14, 2025

$26bn Brighton Jones hires new CFO - Citywire

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic Bio plans liquidation and asset sale By Investing.com - Investing.com South Africa

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic Bio, Apple, Dell And Other Big Stocks Moving Higher In Monday's Pre-Market Session (CORRECTED) - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

12 Health Care Stocks Moving In Monday's Intraday Session - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic outlines plans for dissolution - BioPharma Dive

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic Bio sees initial distribution of $5.13-$5.33 from liquidation - TipRanks

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic Bio stock holds as liquidation plan unveiled By Investing.com - Investing.com Canada

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic Bio Stock Is Up 40% Monday: What's Happening?Third Harmonic Bio (NASDAQ:THRD) - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic Announces Liquidation And Cash Return, Stock Jumps - Nasdaq

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic to shutter; Future Pak once again targets Theratechnologies - Endpoints News

Apr 14, 2025
pulisher
Apr 14, 2025

THRD’s Ambitious Moves: From Trials to Strategies? - timothysykes.com

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic Bio Plans Liquidation With Lucrative Payouts - Finimize

Apr 14, 2025
pulisher
Apr 14, 2025

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic Bio announces plan of liquidation and dissolution - TipRanks

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic Seeks to Liquidate, Dissolve Company - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic Bio Announces Plan Of Liquidation And Dissolution - marketscreener.com

Apr 14, 2025
pulisher
Apr 14, 2025

Third Harmonic Bio plans liquidation and asset sale - Investing.com Australia

Apr 14, 2025

Third Harmonic Bio Inc Stock (THRD) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Third Harmonic Bio Inc Stock (THRD) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Conner Edward R.
Chief Medical Officer
Nov 08 '24
Sale
15.00
2,117
31,755
0
BVF PARTNERS L P/IL
See Explanation of Responses
Oct 29 '24
Sale
14.30
1,000,000
14,300,000
176,692
Conner Edward R.
Chief Medical Officer
Oct 28 '24
Option Exercise
4.20
2,673
11,227
2,673
Conner Edward R.
Chief Medical Officer
Oct 28 '24
Sale
15.00
2,673
40,095
0
$1.08
price up icon 1.89%
$30.12
price down icon 3.67%
$572.87
price down icon 1.12%
$304.56
price up icon 3.75%
$4.50
price down icon 3.02%
$489.52
price down icon 19.09%
Cap:     |  Volume (24h):